Distinguished in Chronic Obstructive Pulmonary Disease (COPD)

Dr. David R. Erb

Pulmonary Medicine | Intensive Care Medicine
151 Harold Fleming Court, 
Spartanburg, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
151 Harold Fleming Court, 
Spartanburg, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Erb is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Spartanburg, South Carolina. Dr. Erb is rated as a Distinguished provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Lung Nodules, Pneumonia, and Advanced Bronchoscopy. Dr. Erb is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 3 clinical trials in the study of Chronic Obstructive Pulmonary Disease (COPD).

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Critical Care Medicine in SC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

151 Harold Fleming Court, Spartanburg, SC 29303

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Recruiting
Publish Date: June 25, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Drug, Device
Study Phase: Phase 4
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 7 Less Clinical Trials

1 Total Publications

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
Journal: NPJ primary care respiratory medicine
Published: September 10, 2020
Similar Doctors
Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Joseph A. Boscia
Pulmonary Medicine
Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Joseph A. Boscia
Pulmonary Medicine

Upstate Lung And Critical Care Specialists PC

151 Harold Fleming Ct, 
Spartanburg, SC 
 (0.1 miles away)
864-573-6320
Languages Spoken:
English, Castilian, Spanish
See accepted insurances
Accepting New Patients

Joseph Boscia is a Pulmonary Medicine provider in Spartanburg, South Carolina. Dr. Boscia is rated as a Distinguished provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, Asbestosis, and Advanced Bronchoscopy. Dr. Boscia is currently accepting new patients.

Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Ifediora F. Afulukwe
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Ifediora F. Afulukwe
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine

Southeastern Hospitalist Services PC

1000 Wellness Way, 
Fort Mill, SC 
 (55.7 miles away)
803-329-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ifediora Afulukwe is a Pulmonary Medicine specialist and a Sleep Medicine provider in Fort Mill, South Carolina. Dr. Afulukwe is rated as a Distinguished provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, End-Stage Renal Disease (ESRD), Pneumonia, and Advanced Bronchoscopy. Dr. Afulukwe is currently accepting new patients.

Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Charles V. Mullen
Intensive Care Medicine | Pulmonary Medicine
Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Charles V. Mullen
Intensive Care Medicine | Pulmonary Medicine

Bon Secours Medical Group Greenville Specialty Care LLC

317 Saint Francis Dr, Suite 220, 
Greenville, SC 
 (29.1 miles away)
864-255-1901
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Mullen is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Greenville, South Carolina. Dr. Mullen is rated as a Distinguished provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Atypical Pneumonia, Hospital-Acquired Pneumonia, and Gastrostomy. Dr. Mullen is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Erb's expertise for a condition
ConditionClose
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile